Síntomas gastrointestinales y tolerancia en lactantes alimentados con fórmula infantil a base de leche de cabra o de vaca (MESK-2)
Efecto de una Fórmula Infantil a Base de Leche de Cabra sobre los Síntomas Gastrointestinales y la Tolerabilidad en Lactantes Sanos a Término: un Ensayo Controlado Aleatorizado a Doble Ciego
This randomized controlled double-blind study will compare the effect of a commercially available goat milk formula to a cow's milk formula on gastrointestinal symptoms and tolerance, and infections in infants.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Jildou Visser, BSc
- Número de teléfono: +31885015283
- Correo electrónico: clinicaltrials@ausnutria.nl
Ubicaciones de estudio
-
-
-
Riyadh, Arabia Saudita
- Reclutamiento
- King Faissal Specialist Hospital & Research Centre
-
Contacto:
- Abdullah Aldowaish, Dr.
- Número de teléfono: 0555878540
- Correo electrónico: dowaish@kfshrc.edu.sa
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age between 14 days and 90 days.
- Healthy singleton term infants born between 37 weeks and 42 weeks of gestation.
- Infants who have received CMF for at least 7 consecutive days.
- Exclusive formula feeding.
- Cow's Milk-related Symptoms Score (CoMiSS®) value at baseline of ≥6 and <10.
- Parents' or caregivers, aged ≥18 years, willing to give informed consent and adhere to study protocol
Exclusion Criteria:
- Exclusively or partially feeding with human milk
- Introduced to solid food, supplementary feeding, use of pre- and/or probiotics as a supplement
- Congenital or recurrent chronic conditions and/or malabsorption that could interfere with study parameters.
- Diagnosed cow's milk allergy (CMA) or suspected to have CMA, soy allergy, fish allergy, egg allergy and/or lactose intolerance.
- Receiving medication (on own initiative or prescription) with regard to FGID (i.e. reflux medication)
- Sibling already participating in this study
- Participation in another clinical trial
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Intervention group
Goat milk-based infant formula |
Study product is administered on demand until the age of 6 months. |
|
Comparador activo: Control group
Cow's milk-based infant formula |
Study product is administered on demand until the age of 6 months. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Gastrointestinal symptoms as determined by CoMiSS
Periodo de tiempo: Difference between groups at Day 14 of the intervention
|
The CoMiSS® is a simple, fast, and easy-to-use awareness tool for cow's milk-related symptoms and may be used in clinical trials to evaluate and quantify the severity of symptoms during a feeding trial. The CoMiSS scores symptoms in five different domains: Crying, Regurgitation, Stools, Skin and Respiratory. The CoMiSS score ranges from 0 to 33 with score 0 as best score (no symptoms) and 33 as worst score (severe symptoms). |
Difference between groups at Day 14 of the intervention
|
|
Gastrointestinal tolerance as determined by IGSQ
Periodo de tiempo: Difference between groups at the end of the intervention at 24 weeks
|
The IGSQ is a 13-item self-report instrument that has been used in clinical trials to assess infants' GI-related signs and symptoms observed by their parents over the previous week in 5 domains: stooling, regurgitation/vomiting, flatulence, crying, and fussiness. The IGSQ has a possible range of 13 to 65, where higher values indicate greater GI distress and values ≤ 23 indicate no digestive distress. |
Difference between groups at the end of the intervention at 24 weeks
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Gastrointestinal symptoms throughout the study as determined by CoMiSS
Periodo de tiempo: From enrollment to the end of the intervention at 24 weeks
|
The CoMiSS® is a simple, fast, and easy-to-use awareness tool for cow's milk-related symptoms and may be used in clinical trials to evaluate and quantify the severity of symptoms during a feeding trial. The CoMiSS scores symptoms in five different domains: Crying, Regurgitation, Stools, Skin and Respiratory. The CoMiSS score ranges from 0 to 33 with score 0 as best score (no symptoms) and 33 as worst score (severe symptoms). |
From enrollment to the end of the intervention at 24 weeks
|
|
Gastrointestinal tolerance throughout the study as determined by IGSQ
Periodo de tiempo: From enrollment to the end of the intervention at 24 weeks
|
The IGSQ is a 13-item self-report instrument that has been used in clinical trials to assess infants' GI-related signs and symptoms observed by their parents over the previous week in 5 domains: stooling, regurgitation/vomiting, flatulence, crying, and fussiness. The IGSQ has a possible range of 13 to 65, where higher values indicate greater GI distress and values ≤ 23 indicate no digestive distress. |
From enrollment to the end of the intervention at 24 weeks
|
|
Occurrence, duration and severity of gastrointestinal infections as determined by Vesikari
Periodo de tiempo: From enrollment to the end of the intervention at 24 weeks
|
The Vesikari Clinical Severity Scoring System includes a e-diary card completed by parents, to identify rotavirus gastroenteritis episodes. The Vesikari Clinical Severity Scoring System Parameters score ranges from 0 to 20 with score <7 as mild symptoms and score 10 to 20 as severe symptoms. |
From enrollment to the end of the intervention at 24 weeks
|
|
Occurrence, duration and severity of respiratory infections as determined by CARIFS
Periodo de tiempo: From enrollment to the end of the intervention at 24 weeks
|
Canadian Acute Respiratory Illness and Flu Scale is a validated parental questionnaire, to measure the disease severity of children with acute respiratory illness (ARI) including influenza. CARIFS consists of 18 items covering three domains; symptoms (e.g., cough); function (e.g., play), and parental impact (e.g., clinginess). Each item is scored 0 to 3, with higher scores indicating greater severity of illness. The full scale ranges from 0 to 58. For children older than 5 years the full scale is used; for children younger than 5 years, 3 items (headache, sore throat, and muscle aches) are not used for assessment. |
From enrollment to the end of the intervention at 24 weeks
|
|
Occurrence, duration and severity of ear infections as determined by AOM-SOS V5
Periodo de tiempo: From enrollment to the end of the intervention at 24 weeks
|
The Acute Otitis Media Symptom Severity scale (AOM-SOS) Version 5.0 is psychometric scale used to measure the severity of symptoms in children with acute otitis media and has been validated for parent-reported use. A 6-point Likert scale ranging from 'No' to 'An extreme amount' is used to rate the presence of 5 symptoms related to acute otitis media over the preceding 24 hours. The AOM-SOS Version 5.0 total score is obtained by summing the scores on these 5 equally-weighted questions. |
From enrollment to the end of the intervention at 24 weeks
|
|
Quality of life as determined by PedsQL
Periodo de tiempo: From enrollment to the end of the intervention at 24 weeks
|
The Pediatric Quality of Life Inventory (PedsQL™) Infant Scales™ is a specific module of the PedsQL™. The objective of this validated questionnaire is to measure generic health-related quality of life in infants. Applicable for infants with acute and chronic health conditions and healthy infants. The questionnaire is composed of 36 items comprising 5 dimensions: physical functioning, physical symptoms, emotional functioning, social functioning and cognitive functioning. Higher scores means better HRQOL and fewer problems or symptoms. A 5-point Likert scale from is applied: 0 (Never) to 4 (Almost always). Scores are transformed on a scale from 0 to 100. |
From enrollment to the end of the intervention at 24 weeks
|
|
Quality of life as determined by WHOQoL-BREF
Periodo de tiempo: From enrollment to the end of the intervention at 24 weeks
|
The World Health Organization Quality of Life Questionnaire BREF (WHOQoL-BREF) is the shortened version of the WHOQoL-100. The WHOQoL-BREF measures quality of life within the context of an individual's culture, value systems, personal goals, standards of concerns. The measuring instrument consists of 26 items. The raw scoreis transformed to a 0-100 scale, where higher scores indicate higher perceived quality of life. |
From enrollment to the end of the intervention at 24 weeks
|
|
Weight
Periodo de tiempo: From enrollment to the end of the intervention at 24 weeks
|
Weight will be measured in kilograms. |
From enrollment to the end of the intervention at 24 weeks
|
|
Height
Periodo de tiempo: From enrollment to the end of the intervention at 24 weeks
|
Height will be measured in centimeters. |
From enrollment to the end of the intervention at 24 weeks
|
|
Head circumference
Periodo de tiempo: From enrollment to the end of the intervention at 24 weeks
|
Head circumference will be measured in centimeters. |
From enrollment to the end of the intervention at 24 weeks
|
|
WHO z-scores
Periodo de tiempo: From enrollment to the end of the intervention at 24 weeks
|
Subject's weight, length and head circumference will be used to calculate the WHO z-scores for weight-for-age, length-for-age, head circumference-for-age, weight-for-length. |
From enrollment to the end of the intervention at 24 weeks
|
|
Fecal parameters
Periodo de tiempo: Baseline, Day 14, Day 28, Week 12 and Week 24
|
The major fecal bacterial groups are defined using 16S RNA sequencing. Further fecal parameters (e.g. pH, SCFA, sIgA, A1AT) are determined with standard laboratory techniques. |
Baseline, Day 14, Day 28, Week 12 and Week 24
|
|
Sleep and Crying episodes
Periodo de tiempo: Baseline, Day 14, Day 28, Week 12 and Week 24
|
Sleep and crying episodes and duration are recorded for 24 hours prior to the visits in diaries. |
Baseline, Day 14, Day 28, Week 12 and Week 24
|
|
Stool frequency & consistenty
Periodo de tiempo: Baseline, Day 14, Day 28, Week 12 and Week 24
|
Stool frequency and consistency are recorded for 24 hours prior to visits in diaries. |
Baseline, Day 14, Day 28, Week 12 and Week 24
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- P24-150
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .